ArticleMayo Clinic proceedings. Innovations, quality & outcomes2024
Trends in the Prescribing of Buprenorphine for Opioid Use Disorder, 2019-2023.
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Policy and Payment Factors Influencing Adoption of Low-Barrier Buprenorphine Treatment.JAMA network open · 2026Article
- Self-Reported History of Precipitated Withdrawal: A Cross-Sectional Study of People Who Use Unregulated Opioids.Journal of addiction medicine · 2026Article
- Implementation facilitation improves readiness for emergency department-initiated buprenorphine to treat opioid use disorder.Journal of substance use and addiction treatment · 2025Article
- Development and Piloting of a Scalable Training for Peer Recovery Specialists in an Evidence-Based Substance Use Intervention: Preliminary Implementation Outcomes.Administration and policy in mental health · 2025Article
- The Effect of Federal Policy Changes on Buprenorphine Prescribing in Massachusetts.Journal of the American College of Emergency Physicians open · 2025Article
- Factors associated with emergency room visits among patients with opioid use disorder: A study of buprenorphine-treated and untreated patients.Drug and alcohol dependence reports · 2025Article
- Health Services Usage in Patients Receiving Buprenorphine for Opioid Use Disorder or Long-Term Opioid Therapy for Chronic Pain: Retrospective Cohort Study.JMIR formative research · 2025Article
- A multi-method spatial examination of factors associated with changes in geographic accessibility to buprenorphine providers in HEALing communities study states Kentucky, Massachusetts, and Ohio.Preventive medicine reports · 2025Article
- Barriers to Buprenorphine Treatment Among People Experiencing Homelessness: A Qualitative Study from the Provider Perspective.Journal of urban health : bulletin of the New York Academy of Medicine · 2025Article
- What waiver? A qualitative exploration of awareness of the X-waiver among underserved patients and providers and the impact on tele-OUD services uptake.Frontiers in psychiatry · 2025Article
- Tracking 5-Year Trends in the Workforce Prescribing Psychotropics and Medications for Opioid Use Disorder: A Cross-Sectional Study.Journal of general internal medicine · 2024Article
- Individuals Dispensed Buprenorphine in the United States Before and After Federal Policy Changes Aimed at Increasing Access.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objective: To evaluate whether access to buprenorphine to treat opioid use disorder (OUD) was associated with the coronavirus disease pandemic, the relaxation of training requirements to obtain an X-Waiver to prescribe buprenorphine (April 2021), and the removal of the X-Waiver (December 2022). Patients and Methods: The OptumLabs Data Warehouse, which includes claims from Commercial and Medicare Advantage enrollees, was used to evaluate trends in prescription fills from January 1, 2019, to June 30, 2023. We compared fill patterns of buprenorphine for OUD with acamprosate to treat alcohol use disorder and naltrexone to treat alcohol use disorder or OUD. We evaluated trends in the rate ratio (RR) of overall fills; RR by days supply; distribution of fills by daily dose; and distribution of fills by prescriber type. Results: Coronavirus disease (RR, 1.06; 95% CI, 1.01-1.11) was associated with a slightly increased rate of fills for Commercial enrollees but not overall or for Medicare Advantage enrollees. There were also no significant increases ( Conclusion: We did not find meaningful improvement in access in response to coronavirus disease or the changes in the X-Waiver. These findings suggest that interventions beyond removing the X-Waiver may be needed to improve buprenorphine access.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.